Aurobindo Pharma Limited has intimated that a Meeting of the Board of Directors will be held on Wednesday, August 5, 2026. The primary agenda is to consider and approve the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026 (Q1 FY27).
Regarding the trading window closure, the company refers to its previous communication dated June 25, 2026, which stated the closure would be effective from July 1, 2026. The closure is now confirmed to extend until 48 hours after the declaration of the results. Specifically, the Trading Window will remain closed up to August 7, 2026, and will re-open on August 8, 2026.
The letter is signed by B. Adi Reddy, Company Secretary, and is digitally signed with a timestamp of July 27, 2026, at 18:06:39 IST. It is addressed to the Listing Departments of both the National Stock Exchange of India Limited (NSE) and BSE Limited.